22:41 , Jun 20, 2019 |  BC Innovations  |  Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Financial News

Beactica completes venture financing

Beactica AB , Uppsala, Sweden   Business: Cancer, Supply/Service   Date completed: 2014-12-15   Type: Venture financing   Raised: Not disclosed   Investors: Almi Invest; Unionen; Uppsala University Holding; private investors; existing investors; company founders...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

Medivir, Beactica deal

Beactica will identify novel hits against an undisclosed “disease-relevant protease of therapeutic interest” for Medivir. The partners declined to disclose details. Medivir AB (SSE:MVIR B), Huddinge, Sweden   Beactica AB , Uppsala, Sweden   Business:...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Company News

Beactica, Boehringer Ingelheim deal

Beactica will use its fragment-based platform to identify selective hits against cancer-relevant kinases selected by Boehringer. Beactica said the project expands a 2008 deal with Boehringer. The partners did not disclose financial details and could...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

Beactica, J&J deal

Johnson & Johnson's Janssen Pharmaceutica N.V. unit and Beactica added the use of Beactica's Sprint surface plasmon resonance (SPR) to identify allosteric modulators targeting undisclosed CNS proteins of interest to Janssen to a 2011 deal....
08:00 , Dec 12, 2011 |  BC Week In Review  |  Company News

Beactica, Almac deal

Beactica will use its Sprint surface plasmon resonance (SPR) drug discovery technology to identify high-quality fragment hits against undisclosed cancer targets from Almac's Almac Discovery Ltd. unit. Almac Discovery said it aims to develop projects...
07:00 , May 2, 2011 |  BC Week In Review  |  Company News

Beactica, J&J deal

Beactica will use its Sprint surface plasmon resonance (SPR) drug discovery technology to generate small molecule compounds against undisclosed targets for Johnson & Johnson's Janssen Pharmaceutica N.V. unit. Financial terms were not disclosed. Beactica AB...
07:00 , Jun 22, 2009 |  BioCentury  |  Emerging Company Profile

Beactica: More Efficient Resonance

Surface plasmon resonance, or SPR, is used in fragment-based drug discovery because it provides a wealth of information about how a compound or fragment interacts with its target. Beactica AB is seeking to improve the...
07:00 , Jun 22, 2009 |  BioCentury  |  Emerging Company Profile

More Efficient Resonance: Sidebar: Corporate Profile

Beactica AB Uppsala, Sweden Technology: Sprint fragment-based drug discovery platform Disease focus: Undisclosed Clinical status: Discovery Founded: 2006 by Per Kallblad and Helena Danielson University collaborators: Uppsala University and Free University of Amsterdam Corporate partners:...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Company News

Beactica, Cubist deal

Beactica will use its Sprint surface plasmon resonance (SPR) screening technology to identify lead candidates against undisclosed pathogenic bacteria proteins for Cubist. Cubist retains rights to resulting IP covering the candidates identified. Further terms were...